Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Stoke Therapeutics, Inc. (Nasdaq: STOK), a pioneering biotechnology company, is focused on restoring protein expression utilizing RNA medicine. Based in Bedford, Massachusetts, Stoke is actively advancing its lead investigational drug, zorevunersen, aimed at treating Dravet syndrome—a severe form of epilepsy. On February 11, 2026, at 2:30 p.m. ET, CEO Ian F. Smith will present at the Guggenheim Emerging Outlook: Biotech Summit 2026, where details about the company’s innovative approaches and developments will be shared. A live audio webcast of the presentation can be accessed through the Investors & News section on Stoke's website.

Stoke’s unique TANGO (Targeted Augmentation of Nuclear Gene Output) methodology focuses on developing antisense oligonucleotides (ASOs) that selectively restore diminished protein levels due to haploinsufficiency, a condition where gene dosage is insufficient. With a current emphasis on central nervous system and ocular diseases, Stoke aims to leverage this innovative technology for broader applications as proof of concept has been shown across various organ systems.

Zorevunersen acts as a disease-modifying agent by increasing the production of the NaV1.1 protein in brain cells, derived from the wild-type SCN1A gene. This strategic mechanism not only seeks to reduce seizure frequency but also enhances neurodevelopment, cognition, and behavior in affected patients. The investigational drug has received significant regulatory designations, including orphan drug status and Breakthrough Therapy Designation from the FDA, highlighting its transformative potential.

Stoke Therapeutics partners with Biogen (Nasdaq: BIIB) for the global development and commercialization of zorevunersen, retaining exclusive rights in the U.S., Canada, and Mexico while granting Biogen rights for the rest of the world. For further inquiries, interested parties can reach out to the company’s media and investor relations teams.

Stoke Therapeutics (Nasdaq: STOK) is poised to capture investor interest at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026, spotlighting its innovative approach to RNA medicine. With the company's lead investigational medicine, zorevunersen, positioned as a first-in-class therapy for Dravet syndrome, investors should consider the implications of this presentation for future stock performance.

Stoke’s proprietary TANGO platform aims to restore essential protein levels in patients with haploinsufficiency disorders. Given the promising data from the ongoing Phase 3 trial of zorevunersen—which focuses on increasing functional NaV1.1 protein production to alleviate seizures—there is a potential for significant clinical milestones, particularly as the FDA has granted Breakthrough Therapy Designation and orphan drug status. These designations can accelerate development timelines and enhance market perception.

The collaboration with Biogen provides a robust strategic advantage, as it allows Stoke to maintain exclusive commercialization rights in North America while gaining access to Biogen's extensive global marketing capabilities. This partnership not only enhances Stoke’s financial standing but also validates the science behind its differentiated treatment approach, given Biogen's established presence in the neurology sector.

Investors should closely monitor the outcomes from the Phase 3 study, especially data related to improvement in neurodevelopment and cognition, which could set zorevunersen apart from existing seizure medications. A favorable presentation at the upcoming summit could lead to heightened visibility and potentially increased share value, as it underscores Stoke's leadership role in addressing unmet medical needs in the neurology space.

In conclusion, with a strong pipeline and strategic industry alliances, Stoke Therapeutics presents a compelling opportunity for investors focused on biotech innovations. The upcoming summit could serve as a catalyst for further market engagement and strategic investment decisions.